Preclinical evaluation and molecular docking of 1,3-benzodioxole propargyl ether derivatives as novel inhibitor for combating the histone deacetylase enzyme in cancer

SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

(2017) Antoine Daina et al.   Scientific Reports

Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates

(2013) Christopher J. Millard et al.   MOLECULAR CELL

Protein docking using case-based reasoning

(2013) Anisah W. Ghoorah et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

Computational identification of novel histone deacetylase inhibitors by docking based QSAR

(2012) Syam B. Nair et al.   COMPUTERS IN BIOLOGY AND MEDICINE

Appraisal of GABA and PABA as linker: Design and synthesis of novel benzamide based histone deacetylase inhibitors

(2012) Harish Rajak et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

DOGS: Reaction-Driven de novo Design of Bioactive Compounds

(2012) Markus Hartenfeller et al.   PLoS Computational Biology

Therapeutic Potential for HDAC Inhibitors in the Heart

(2011) Timothy A. McKinsey   Annual Review of Pharmacology and Toxicology

Toward in silico structure-based ADMET prediction in drug discovery

(2011) Gautier Moroy et al.   DRUG DISCOVERY TODAY

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

(2011) Omar Khan et al.   IMMUNOLOGY AND CELL BIOLOGY

Design, synthesis, and biological evaluation of novel 2,4-thiazolidinedione derivatives as histone deacetylase inhibitors targeting liver cancer cell line

(2011) Rhea Mohan et al.   MEDICINAL CHEMISTRY RESEARCH

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

(2010) Jiahuai Tan et al.   Journal of Hematology & Oncology

Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining

(2010) Kyle M Miller et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Histone deacetylases and epigenetic therapies of hematological malignancies

(2010) Ciro Mercurio et al.   PHARMACOLOGICAL RESEARCH

Focal Nature of Neurological Disorders Necessitates Isotype-Selective Histone Deacetylase (HDAC) Inhibitors

(2009) Elizabeth A. Thomas   MOLECULAR NEUROBIOLOGY

Medicinal Chemistry and the Molecular Operating Environment (MOE): Application of QSAR and Molecular Docking to Drug Discovery

(2008) Santiago Vilar et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

(2008) M. Fournel et al.   MOLECULAR CANCER THERAPEUTICS

Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation

(2008) C. K. Hahn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA